Sunny Abraham,Shripad S. Bhagwat,Brian T. Campbell,Qi Chao,Raffaella Faraoni,Mark W. Holladay,Andiliy G. Lai,Martin W. Rowbottom,Eduardo Setti,Kelly G. Sprankle
申请号：
US14605834
公开号：
US09320739B2
申请日:
2015.01.26
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
